Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Akebia Ther

Healthcare US AKBA

1.1USD
0.01(0.92%)

Last update at 2026-06-23T20:27:00Z

Day Range

1.091.14
LowHigh

52 Week Range

1.144.08
LowHigh

Fundamentals

  • Previous Close 1.09
  • Market Cap377.71M
  • Volume2387446
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA27.27M
  • Revenue TTM236.20M
  • Revenue Per Share TTM0.92
  • Gross Profit TTM 195.84M
  • Diluted EPS TTM-0.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -3.72100M -69.41000M -51.92500M -92.56200M -282.84000M
Minority interest - - - - -
Net income -5.34500M -69.41000M -51.92500M -106.00900M -244.87000M
Selling general administrative 107.48M 101.94M 3.24M 141.87M 177.65M
Selling and marketing expenses - 4.60M 100.23M -3.17500M 174.16M
Gross profit 196.73M 97.00M 120.47M 207.81M 60.18M
Reconciled depreciation 1.27M 37.50M 37.64M 37.70M 37.97M
Ebit 20.46M -51.22500M -45.89300M -63.18200M -303.28800M
Ebitda 21.73M -13.72100M -8.26600M -46.34300M -265.31800M
Depreciation and amortization 1.27M 37.50M 37.63M 16.84M 37.97M
Non operating income net other - - - 2.24M 2.41M
Operating income 23.50M -50.47200M -46.25600M -63.18200M -265.31800M
Other operating expenses 212.70M 210.65M 240.88M 355.78M 478.90M
Interest expense 24.18M 18.18M 6.03M 15.69M -19.93600M
Tax provision 1.62M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income - - - - -
Net interest income -24.17900M -18.18500M -6.25000M -15.68700M -19.93600M
Extraordinary items - - - - -
Non recurring - - - 15.93M -
Other items - - - - -
Income tax expense 1.62M - 41.68M 13.45M -37.97000M
Total revenue 236.20M 160.18M 194.62M 292.60M 213.58M
Total operating expenses 173.24M 147.47M 166.73M 270.99M 325.50M
Cost of revenue 39.46M 63.18M 74.15M 84.80M 153.39M
Total other income expense net -27.22000M -18.93800M -5.66900M -29.38000M -17.52200M
Discontinued operations - - - - -
Net income from continuing ops -5.34500M -69.41000M -56.94600M -92.56200M -282.84000M
Net income applicable to common shares - - - -92.56200M -282.84000M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 376.56M 220.67M 241.70M 351.83M 525.55M
Intangible assets - - 36.04M 72.08M 108.13M
Earning assets - - - - -
Other current assets -62.64100M 11.35M 20.24M 33.54M 33.14M
Total liab 343.95M 269.86M 272.29M 342.49M 449.09M
Total stockholder equity 32.61M -49.18500M -30.58400M 9.34M 76.46M
Deferred long term liab - - - - -
Other current liab 101.67M 56.02M 38.26M 66.25M 99.65M
Common stock 0.00200M 0.00200M 0.00200M 0.00200M 0.00100M
Capital stock 0.00200M 0.00200M 0.00200M 0.00200M 0.00100M
Retained earnings -1683.70500M -1678.36000M -1608.95000M -1552.91300M -1460.35100M
Other liab - - - 158.25M 158.90M
Good will 59.04M 59.04M 59.04M 55.05M 55.05M
Other assets - - - 94.48M 640.27M
Cash 184.84M 51.87M 42.92M 90.47M 149.80M
Cash and equivalents - - - - -
Total current liabilities 162.94M 80.91M 99.87M 124.76M 256.49M
Current deferred revenue - 15.73M 22.94M 3.74M 20.91M
Net debt 31.45M 136.86M 61.26M 9.32M -13.75200M
Short term debt 40.08M 9.71M 24.04M 36.74M 102.34M
Short long term debt - - 17.50M 32.00M 97.54M
Short long term debt total 216.30M 188.73M 104.18M 99.78M 136.05M
Other stockholder equity 1716.31M 1629.17M 1578.36M 1562.25M 1536.80M
Property plant equipment - - - 5.21M 6.75M
Total current assets 184.84M 113.83M 118.15M 184.95M 272.01M
Long term investments - - - - -
Net tangible assets - - - -117.79500M -86.72400M
Short term investments - - - - 0.00000M
Net receivables 47.03M 34.37M 39.29M 39.18M 50.88M
Long term debt 48.25M 38.69M 17.18M 34.08M 1.82M
Inventory 15.61M 16.24M 15.69M 21.76M 38.20M
Accounts payable 21.18M 15.18M 14.63M 18.02M 33.59M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00600M 0.00600M 0.00600M 0.00600M 0.00600M
Additional paid in capital - - - - -
Common stock total equity - - - 0.00200M 0.00100M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -1552.91300M -1460.35100M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 132.68M 37.38M 10.77M 5.37M 49.75M
Deferred long term asset charges - - - - -
Non current assets total 191.72M 106.84M 123.55M 166.88M 253.54M
Capital lease obligations 3.55M 8.95M 13.44M 33.70M 38.51M
Long term debt total - - - - 1.82M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.03300M 0.00000M -0.11400M 40.00M
Change to liabilities - - - -34.64600M -48.89600M
Total cashflows from investing activities -7.92600M -0.03300M - -0.11400M 39.94M
Net borrowings 9.54M 7.90M -32.00000M -33.00000M -33.00000M
Total cash from financing activities 72.93M 49.66M -25.20600M 14.60M 133.73M
Change to operating activities - - - -37.98200M -48.63500M
Net income -5.34500M -69.41000M -51.92500M -92.56200M -282.84000M
Change in cash 132.99M 8.97M -48.59000M -58.67000M -79.29300M
Begin period cash flow 53.55M 44.58M 93.17M 151.84M 231.13M
End period cash flow 186.54M 53.55M 44.58M 93.17M 151.84M
Total cash from operating activities 67.99M -40.65900M -23.38400M -73.15400M -252.96500M
Issuance of capital stock 66.68M 42.65M -0.00100M 7.12M 88.20M
Depreciation 1.27M 37.50M 41.85M 37.70M 37.97M
Other cashflows from investing activities -7.92600M - - - -
Dividends paid - - - - -
Change to inventory -23.12500M -28.40100M -2.54200M 19.79M -25.84700M
Change to account receivables -14.14200M 4.05M 0.99M 11.70M -24.02200M
Sale purchase of stock - -1.27200M 0.00000M 7.60M 88.95M
Other cashflows from financing activities -0.06300M 0.39M 0.00100M 40.48M 45.53M
Change to netincome - - - 46.73M 37.08M
Capital expenditures 0.29M 0.03M 0.00000M 0.11M 0.06M
Change receivables - - - 11.70M -24.02200M
Cash flows other operating - - - -61.86600M 53.61M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -58.67000M -79.29300M
Change in working capital 16.47M -39.67600M -20.72700M -1.43500M -108.41800M
Stock based compensation 11.28M 7.78M 9.32M 17.85M 22.73M
Other non cash items 44.31M 23.15M -1.89500M -34.70300M 41.01M
Free cash flow 67.99M -40.69200M -23.38400M -73.26800M -253.02400M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AKBA
Akebia Ther		 0.01 0.92% 1.10 - 35.71 1.60 11.75 1.06 11.51
ZTS
Zoetis Inc		 0.95 1.25% 76.84 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 0.42 1.37% 30.98 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 6.43 4.31% 155.71 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 0.48 1.12% 43.42 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Akebia Ther

245 First Street, Cambridge, MA, United States, 02142

Key Executives

Name Title Year Born
Mr. John P. Butler MBA CEO, Pres & Director 1964
Mr. David A. Spellman Sr. VP, CFO & Treasurer 1977
Mr. Michel Dahan Sr. VP & COO 1979
Dr. Steven Keith Burke Sr. VP of R&D and Chief Medical Officer 1961
Ms. Violetta Cotreau Sr. VP, Chief Accounting Officer & Principal Accounting Officer 1973
Ms. Nicole R. Hadas Sr. VP, Chief Legal Officer & Sec. 1973
Mercedes Carrasco Director of Corp. Communications NA
Mr. Douglas Jermasek M.B.A. VP of Marketing & Strategy NA
Ms. Meredith Bowman Sr. VP of People NA
Dr. Thierry Bilbault Ph.D. Sr. VP of Manufacturing & Pharmaceutical Devel. 1959

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.